To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Clinical trial NCT04551053 · TERMINATED

Trial details

NCT number: NCT04551053
Sponsor: Incyte Corporation
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Myelofibrosis Primary Myelofibrosis Post Essential Thrombocythemia Myelofibrosis Post Polycythemia Vera Myelofibrosis

Start date: 2021-05-26
Primary completion: 2023-08-16
Enrollment: 177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.